 Home > Active Ingredient News > Antitumor Therapy > Cancer: The effect of HIV-1 protease inhibitor nelfinavir combined with standard radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer

Cancer: The effect of HIV-1 protease inhibitor nelfinavir combined with standard radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer

 Last Update: 2021-05-20
 Source: Internet
 Author: User

Tags

avelumab bladder cancer

ind clinical trial

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Nelfinavir (Nelfinavir, NFV) is an HIV-1 protease inhibitor that has been shown to increase the sensitivity of cancer cells to chemical radiation (CRT) .

Nelfinavir (NFV) is an HIV-1 protease inhibitor that has been shown to increase the sensitivity of cancer cells to chemical radiation (CRT)

This study is a phase 1 clinical trial to evaluate the safety of NFV for locally advanced cervical cancer and determine the recommended phase 2 clinical trial dose of NFV combined with simultaneous CRT for the treatment of locally advanced cervical cancer.

Two dose levels of NFV were evaluated: 875 mg, oral, 2/day (dose level 1 [DL1]) and 1250 mg, oral, 2/day (DL2).

immunity

Research design

Research results show that NFV ground can indeed increase the sensitivity of cervical cancer cells to radiotherapy, increase cell apoptosis, and enhance tumor suppression in vivo .

NFV ground can indeed increase the sensitivity of cervical cancer cells to radiotherapy, increase cell apoptosis, and enhance the anti- tumor effect in vivo NFV ground can indeed increase the sensitivity of cervical cancer cells to radiotherapy, increase cell apoptosis, and enhance the anti-tumor effect in vivo

In the DL1 group, after one patient had dose-limiting toxicity, 6 patients required dose expansion, while patients in the DL2 group had no dose-limiting toxicity.

DL2 is determined as the recommended phase 2 dose

Tumor volume treated by different regimens

All patients in the DL2 group completed CRT, and 1 out of 6 patients developed grade 3/4 anemia, nausea, and diarrhea.

During a median follow-up of 50 months, 10 of 11 evaluable patients still showed no signs of disease recurrence .

During a median follow-up of 50 months, 10 of 11 evaluable patients still showed no signs of disease recurrence

Changes of tumor histochemical staining before and after NFV treatment

In addition, NFV can significantly reduce the level of phosphorylated Akt in tumors.

In short, CRT combined with NFV is well tolerated .

CRT combined with NFV is well tolerated CRT combined with NFV is well tolerated

Original source:

Garcia-Soto Arlene E, McKenzie Nathalie D, Whicker Margaret E et al.

org/10.
1002/cncr.
33449">Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.